CoChat

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

Open access
Li, Dapeng, Martinez, David R., Schäfer, Alexandra, Chen, Haiyan, Barr, Maggie, Sutherland, Laura L., Lee, Esther, Parks, Robert, Mielke, Dieter, Edwards, Whitney, Newman, Amanda, Bock, Kevin W., Minai, Mahnaz, Nagata, Bianca M., Gagne, Matthew, Douek, Daniel C., DeMarco, C. Todd, Denny, Thomas N., Oguin, Thomas H., Brown, Alecia, Rountree, Wes, Wang, Yunfei, Mansouri, Katayoun, Edwards, Robert J., Ferrari, Guido, Sempowski, Gregory D., Eaton, Amanda, Tang, Juanjie, Cain, Derek W., Santra, Sampa, Pardi, Norbert, Weissman, Drew, Tomai, Mark A., Fox, Christopher B., Moore, Ian N., Andersen, Hanne, Lewis, Mark G., Golding, Hana, Seder, Robert, Khurana, Surender, Baric, Ralph S., Montefiori, David C., Saunders, Kevin O., Haynes, Barton F. · 2022 · Nature Communications

Published version of a preprint

Cited by 74

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that induced neutralizing antibodies against SARS-CoV-2 and pre-emergent sarbecoviruses and protected non-human primates (NHPs) from SARS-CoV-2 WA-1 infection. Here, we find the RBD-scNP induced neutralizing antibodies in NHPs against pseudoviruses of SARS-CoV and SARS-CoV-2 variants including 614G, Beta, Delta, Omicron BA.1, BA.2, BA.2.12.1, and BA.4/BA.5, and a designed variant with escape mutations, PMS20. Adjuvant studies demonstrate variant neutralization titers are highest with 3M-052-aqueous formulation (AF). Immunization twice with RBD-scNPs protect NHPs from SARS-CoV-2 WA-1, Beta, and Delta variant challenge, and protect mice from challenges of SARS-CoV-2 Beta variant and two other heterologous sarbecoviruses. These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-33985-4

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 33

  1. Wang, L. & Cheng, G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. J. Med. Virol., https://doi.org/10.1002/jmv.27516 (2021). · DOI · Paper page
  2. Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022). · DOI · Paper page
  3. Yamasoba, D. et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell, https://doi.org/10.1016/j.cell.2022.04.035 (2022). · DOI · Paper page
  4. Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. bioRxiv https://doi.org/10.1101/2022.04.30.489997 (2022). · DOI
  5. Schmidt, F. et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512–516 (2021). · DOI · Paper page
  6. Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell 184, 4203–4219 e4232 (2021). · DOI · Paper page
  7. Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P.& Haynes, B. F. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu. Rev. Med., https://doi.org/10.1146/annurev-med-042420-113838 (2021). · DOI · Paper page
  8. Hastie, K. M. et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science 374, 472–478 (2021). · DOI · Paper page
  9. Martinez, D. R. et al. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Sci. Transl. Med., 14, eabj7125 (2021). · DOI · Paper page
  10. Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042.e1021 (2020). · DOI · Paper page
  11. Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185, 1556–1571.e1518 (2022). · DOI · Paper page
  12. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, https://doi.org/10.1038/s41586-021-04386-2 (2021). · DOI · Paper page
  13. Hachmann, N. P. et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 387, 86–88 (2022). · DOI · Paper page
  14. Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492–503 (2010). · DOI · Paper page
  15. HogenEsch, H., O’Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3, 51 (2018). · DOI · Paper page
  16. Routhu, N. K. et al. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nat. Commun. 12, 3587 (2021). · DOI
  17. Kasturi, S. P. et al. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates. Sci. Immunol. 5, https://doi.org/10.1126/sciimmunol.abb1025 (2020). · DOI · Paper page
  18. Smirnov, D., Schmidt, J. J., Capecchi, J. T. & Wightman, P. D. Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine 29, 5434–5442 (2011). · DOI · Paper page
  19. Fox, C. B. et al. Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. J. Control Release 244, 98–107 (2016). · DOI
  20. Fox, C. B., Kramer, R. M., Barnes, V. L., Dowling, Q. M. & Vedvick, T. S. Working together: interactions between vaccine antigens and adjuvants. Ther. Adv. Vaccines 1, 7–20 (2013). · DOI
  21. Dai, L. et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell 182, 722–733.e711 (2020). · DOI · Paper page
  22. Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572–577 (2020). · DOI · Paper page
  23. Francica, J. R. et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci. Transl. Med. 13, https://doi.org/10.1126/scitranslmed.abi4547 (2021). · DOI · Paper page
  24. Pino, M. et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci. Immunol. 6, https://doi.org/10.1126/sciimmunol.abh3634 (2021). · DOI
  25. Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science 373, 991–998 (2021). · DOI · Paper page
  26. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020). · DOI · Paper page
  27. Zhou, T. et al. Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes. Cell Rep. 33, 108322 (2020). · DOI · Paper page
  28. Freyn, A. W. et al. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol. Ther. Methods Clin. Dev. 22, 84–95 (2021). · DOI
  29. Baiersdorfer, M. et al. A facile method for the removal of dsrna contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26–35 (2019). · DOI · Paper page
  30. Berry, J. D. et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J. Virol. Methods 120, 87–96 (2004). · DOI · Paper page
  31. Sanchez, A. M. et al. Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. J. Immunol. Methods 409, 117–130 (2014). · DOI
  32. Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21, 1508–1513 (2015). · DOI · Paper page
  33. Roberts, A. et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog. 3, e5 (2007). · DOI · Paper page

Cited by

See all 74

Metadata

Authors
Li, D., Martinez, D. R., Schäfer, A., Chen, H., Barr, M., Sutherland, L. L., Lee, E., Parks, R., Mielke, D., Edwards, W., Newman, A., Bock, K. W., Minai, M., Nagata, B. M., Gagne, M., Douek, D. C., DeMarco, C. T., Denny, T. N., Oguin, T. H., Brown, A., Rountree, W., Wang, Y., Mansouri, K., Edwards, R. J., Ferrari, G., Sempowski, G. D., Eaton, A., Tang, J., Cain, D. W., Santra, S., Pardi, N., Weissman, D., Tomai, M. A., Fox, C. B., Moore, I. N., Andersen, H., Lewis, M. G., Golding, H., Seder, R., Khurana, S., Baric, R. S., Montefiori, D. C., Saunders, K. O., & Haynes, B. F.
Venue
Nature Communications
Published
2022-10-23
Volume
13
Issue
1
Pages
6309-6309
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4307099094
Cited by
74
References
32
FWCI
7.37
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. https://app.cochat.ai/papers/10.1038/s41467-022-33985-4
The paper
Li, D., Martinez, D. R., Schäfer, A., Chen, H., Barr, M., Sutherland, L. L., Lee, E., Parks, R., Mielke, D., Edwards, W., Newman, A., Bock, K. W., Minai, M., Nagata, B. M., Gagne, M., Douek, D. C., DeMarco, C. T., Denny, T. N., Oguin, T. H., . . . Haynes, B. F. (2022). Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. Nature Communications. https://doi.org/10.1038/s41467-022-33985-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.